CXCL8 and neoplasm: Elevated plasma interleukin-8 (IL-8) may also inhibit antigen presentation in tumor cells and appears to decrease response to checkpoint inhibition therapy in patients undergoing atezolizumab treatment in metastatic renal cell cancer [69].